The annual sales of urinary incontinence drugs is $3.4 billion, and the two varieties lead the domestic public hospital market

This week is the world urinary incontinence week, which was established by the International Association for urinary control in 2009 The time is from Monday to Friday at the end of June every year According to foreign statistical data, 10% - 15% of middle-aged and elderly people in the world suffer from different degrees of urinary incontinence, which is called as overactive bladder (OAB) in medicine The survey shows that women over 60 years old and men over 65 years old are the main groups of this disease The results of large-scale epidemiological survey of overactive bladder in China show that the overall prevalence of overactive bladder in Chinese adults is 5.9% With the increase of age, the overactive bladder syndrome is gradually increasing In addition, according to the statistical analysis of the number of outpatients in the hospital, the treatment rate of overactive bladder in China is only 0.38% Due to the low recognition rate of mild to moderate overactivity of bladder and the relatively low medical treatment rate, the growth of overactivity of bladder Market in China is slow   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> guide update leads OAB management In November 2017, the society of Obstetricians and Gynaecologists of Canada (SOGC) updated the guidelines for the treatment of overactivity of the bladder This update focuses on the content of drug treatment As a supplement to document No 283 issued in 2012, the content includes the anticholinergic drug fexolodine, the β 3-receptor agonist milabellone, and the combined therapy of anticholinergic drug and β 3-receptor agonist 。 In 2014, the American Urological Association and the society of urodynamics and female urology (AUA / Sufu) updated the diagnosis and treatment guidelines for overactivity of the bladder, making it clear that the β 3-adrenoceptor agonist myrbetriq is the first-line or second-line treatment option for a certain type of patients; Botox A is recommended as the "standard program" for the third-line treatment According to a research report by giobia IData, the global market for treatment of urinary incontinence in 2017 was about US $3.4 billion, with a small growth rate in fact   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; Color: rgb (62, 62, 62); border style: none none solid; text align: Center; border bottom width: 1px; border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> mirabegron is a new type of OAB treatment drug developed by Japan's Astaire company It was listed in Japan on September 16, 2011, under the trade name betanis, and approved by the US FDA in June 2012 for the treatment of adult overactive bladder (OAB), under the trade name of myrbetriq In 2016, the sales volume of milabellon of anstela company in seven major markets in the world was $796 million In December 2017, it was approved by CFDA to be listed in China under the name of betmiga Milabellon compound patent expires in 2018 Many domestic manufacturers have already been developing rapidly Seven companies, including Zhejiang Jingxin Pharmaceutical Co., Ltd., Jiangsu Deyuan Pharmaceutical Co., Ltd and Ruiyang Pharmaceutical Co., Ltd., have entered the research and development Milabellone is a potential selective β 3-adrenoceptor agonist, which can enhance the bladder filling and urine storage capacity by activating the β 3-adrenoceptor on the bladder muscle It is the first drug approved by FDA in the past 30 years to treat OAB with a new mechanism The drug can relax the smooth muscle of detrusor during the storage period of bladder filling micturition cycle, relieve the symptoms of urinary frequency caused by overactivity of bladder and promote the increase of bladder capacity Overactive bladder is a syndrome characterized by urgency, frequency and urgency of urinary incontinence With good efficacy and tolerance, it has been recommended by many guidelines, especially for OAB patients with bladder detrusor weakness   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> as a common clinical disease, bladder overactivity can be caused by mental factors, nervous system diseases, childbirth, trauma and other factors The incidence of women is more than twice that of men Severe overactivity of bladder can be treated by operation, but most of the elderly suffer from hypertension, hyperglycemia and other diseases, and operation has certain risks Therefore, according to the different degree of the disease, conservative drug treatment can be considered for mild and moderate urinary incontinence With the rapid arrival of the global aging society, drug research and development institutions have focused on the field of overactive bladder drugs At present, the main clinical drugs for overactivity of bladder in domestic hospitals are tolterodine, oxybutynin, pyruvate, solinacin, propervillin and troxerox According to CFDA official website data, the new diphenyl butylamide anticholinergic drug imidafenacin, which was originally developed by Ono pharmaceutical and Xinglin pharmaceutical in Japan, and feroterodine, Novartis and darifenacin of Pfizer, have been intensively declared in China   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> in the domestic public hospital market, the two varieties account for more than 60% According to the data of minenet, in 2017, the drug market for overactive bladder in 400 public sample hospitals in 16 key cities in China was 52.2 million yuan, an increase rate of 16.54% over the previous year Solanesin and tolterodine accounted for 66.27% of the total market   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; Color: rgb (62, 62, 62); border style: none solid; text align: Center; border bottom width: 1px; border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> solina, the leader of solina new public hospital, is a competitive cholinergic receptor blocker developed by astras pharmaceutical company In August 2004, it was first listed in the Netherlands, Germany, the UK, France and Denmark In November 2004, it was approved by FDA to enter the U.S market In 2009, solina new tablet was approved by the State Drug Administration of China for clinical use, with the trade name of vesicare In 2016, the global vesicare market was $945 million According to the latest data of mienei.com, in 2017, the amount of sulina new drug used in 400 public sample hospitals in 16 key cities in China was 17.97 million yuan, with a year-on-year growth rate of 11.60% Solinacin is a competitive cholinergic receptor blocker It can selectively block cholinergic receptor and relax smooth muscle, so as to relieve the symptoms of urinary frequency, urgency and incontinence Weixikang can stimulate saliva secretion and has good tolerance Compared with the traditional anticholinergic drugs, tolterodine and oxibunin, its adverse reactions such as dry mouth, constipation and blurred vision are significantly reduced According to the data on CFDA's official website, Qilu Pharmaceutical Co., Ltd., Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., Lepu Pharmaceutical Co., Ltd., Sichuan Ruikang Pharmaceutical Co., Ltd., Jiangsu Shenlong Pharmaceutical Co., Ltd., etc are under development   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; Color: rgb (62, 62, 62); border style: none solid; text align: Center; border bottom width: 1px; border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> 20.62% growth rate of Tristram is an anticholinergic compound, which was approved by FDA on May 28, 2004 Tristram is a powerful M receptor blocker with high affinity for ml and M3 receptors It can relax bladder smooth muscle and relieve the contraction of smooth muscle which leads to OAB symptoms It is used for the treatment of overactivity of bladder with the symptoms of urgent incontinence China's State Food and drug administration has approved the listing of trimethylammonium chloride tablets of medapharma GmbH & Co.KG in Germany under the trade name of Spasmo Lyt There are three listed companies in China, namely Yangzijiang Pharmaceutical Group, shutaishen (Beijing) bio pharmaceutical and Shouguang Fukang pharmaceutical According to the latest data of minenet, in 2017, the amount of triamchloramine used in 400 public sample hospitals in 16 key cities in China increased by 20.62% year on year, and Yangzijiang Pharmaceutical Group occupied the main market   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> tolterodine is a new generation of competitive M3 receptor antagonist developed by Pfizer It was approved by FDA to be listed in the United States in 1998, and its trade name is detrol la It is the most prescribed OAB treatment drug at present, with a peak sales of more than 1.2 billion US dollars With the expiration of patent in 2012 and the replacement of products